Biotech entity
The clearest coverage concentration is pharma: 4 of 5 stories, with the rest divided among 1 other category. They are better corroborated than the beat average, carrying 30 original sources each against 3.8 for the same window. Negative sentiment reaches 0% here, compared with 19% across the 570-story beat baseline for the same window.
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 4 of 5 stories, with the rest divided among 1 other category. They are better corroborated than the beat average, carrying 30 original sources each against 3.8 for the same window. Negative sentiment reaches 0% here, compared with 19% across the 570-story beat baseline for the same window. Of the tracked stories, 2 of 5 also mention FDA, the most common co-covered peer. That works out to roughly 0.2 stories per week across a 156-day span. At 5.8, the average consequence score sits below the same-window beat average of 6.2. We currently track 5 Biotech stories that mention Amgen, published between February 22, 2026 and July 27, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 570 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amgen. Shared-story counts are live from our verified record — not editorial picks.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Drugmaker copay assistance programs are meant to lower barriers to high-cost specialty drugs, but accumulator programs circumvent them. For Amgen and other pharma companies, this practice threatens patient adherence and undermines the value of patient support initiatives.
Source: mcall.com · journal-advocate.com
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Source: kingstonthisweek.com · shorelinebeacon.com
Amgen is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
